Fresenius Medical Care North America Comments on Voter’s Overwhelming Rejection of Proposition 23 in California
WALTHAM, Mass. – Nov. 4, 2020 - Fresenius Medical Care North America (FMCNA), the nation's leading renal care company, today released the following statement in response to the overwhelming rejection of the ballot initiative Proposition 23 in California.
“It’s good news for patients that California voters have sided with a wide coalition of healthcare providers rejecting Proposition 23,” said Bill Valle, CEO of Fresenius Medical Care North America. “This result is in the patients' best interest as it safeguards access to dialysis in California by avoiding redundant and unnecessary requirements. The overwhelming vote against Proposition 23 allows us to maintain our focus on providing the highest quality care possible for our patients needing life-sustaining treatment.”
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com/.
